5-[(3-{[(2-chlorophenyl)amino]carbonylamino}-5-[N-(6-sulfonaphthyl)carbamoyl]phenyl)carbonylamino]naphthalene-2-sulfonic acid | 325980-88-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-[(3-{[(2-chlorophenyl)amino]carbonylamino}-5-[N-(6-sulfonaphthyl)carbamoyl]phenyl)carbonylamino]naphthalene-2-sulfonic acid
• 英文别名: 5-[[3-[(2-Chlorophenyl)carbamoylamino]-5-[(6-sulfonaphthalen-1-yl)carbamoyl]benzoyl]amino]naphthalene-2-sulfonic acid
• CAS: 325980-88-9
• 化学式: C₃₅H₂₅ClN₄O₉S₂
• 分子量: 745.19
• InChiKey: IQJNOJUNLVJIOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  51
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  225
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  5-({3-amino-5-[N-(6-sulfonaphthyl)carbamoyl]phenyl}carbonylamino)naphthalene-2-sulfonic acid 、 1,2,4-三氯萘 在 吡啶 作用下， 以 四氢呋喃 、 N-甲基乙酰胺 为溶剂， 生成 5-[(3-{[(2-chlorophenyl)amino]carbonylamino}-5-[N-(6-sulfonaphthyl)carbamoyl]phenyl)carbonylamino]naphthalene-2-sulfonic acid
  参考文献：
  名称：

  Naphthylsulfonic acids and related compounds as glucose uptake agonists

  摘要：

  使用新型萘磺酸和相关化合物治疗与高血糖相关的疾病，特别是II型糖尿病的方法。这些化合物，作为单一立体异构体或立体异构体混合物，或它们的药用可接受盐，在刺激胰岛素受体的激酶活性、增强胰岛素对胰岛素受体的激活以及促进葡萄糖进入细胞的方法中具有用途。还披露了各种抗糖尿病化合物和包含这些抗糖尿病化合物的药物组合物。

  公开号：

  US06653321B1

文献信息

• NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS
  申请人：TELIK, INC.

  公开号：EP1200396A1

  公开（公告）日：2002-05-02
• US6653321B1
  申请人：——

  公开号：US6653321B1

  公开（公告）日：2003-11-25
• [EN] NOVEL NAPHTHYLSULFONIC ACIDS AND RELATED COMPOUNDS AS GLUCOSE UPTAKE AGONISTS<br/>[FR] NOUVEAUX ACIDES NAPHTYLSULFONIQUES ET COMPOSES APPARENTES UTILISES COMME AGONISTES DE CAPTAGE DU GLUCOSE
  申请人：TELIK INC

  公开号：WO2001012591A1

  公开（公告）日：2001-02-22

  Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthylsulfonic acids and related compounds are provided. Compounds of formula (1) where: R?1 and R2¿ are, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, R3 is a substituent on the B ring; and is -SO¿2OR?6, -C(O)OR6, -SO2NR62-C(O)NR62 or tetrazolyl; the linker -WY- between the naphthyl and phenyl intersects the A ring of the naphthyl and is, independently, -C(O)NR?7-, -NR7¿C(O)-, -C(O)O-, -OC(O)-, -CH=CH-, -NR7CH2-, -CH2NR?7-, -NR7C(O)NR7- -NR7¿C(O)O-, -OC(O)NR?7-, -NR7SO¿2O-, -OSO2NR7-, -OC(O)O-, -SO¿2?NR?7-, -NR7SO¿2-, -OSO2-, or -SO2O-; each R?6 and R7¿ is, independently, hydrogen or lower alkyl; optionally in the form of single stereoisomers or mixtures of stereoisomers, or the pharmaceutically acceptable salts thereof; are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.